Laurice T Yang, MD
Neuropsychiatry · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 5
- 2 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
5 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Yang’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
5 of 5 plans
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A113191 · Current
Licensed to practise in California · since 2010 · expires 2027-11-30 · University of Vermont College of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$47,557
Medicare paid this office $47,557 for 115 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 47 | $14,093 | $168 |
| Long return visit (40+ min) | 57 | $12,121 | $115 |
| Return visit (30+ min) | 31 | $3,868 | $102 |
| Face injection for nerve paralysis | 11 | $3,824 | $147 |
| Injection of chemical for paralysis of nerve muscles on arm or leg, 1-4 muscles, first extremity | 14 | $2,481 | $75 |
See all 7 services
| Long return visit (40+ min) | 47 | $14,093 | $168 |
| Long return visit (40+ min) | 57 | $12,121 | $115 |
| Return visit (30+ min) | 31 | $3,868 | $102 |
| Face injection for nerve paralysis | 11 | $3,824 | $147 |
| Injection of chemical for paralysis of nerve muscles on arm or leg, 1-4 muscles, first extremity | 14 | $2,481 | $75 |
| Return visit (30+ min) | 19 | $1,871 | $81 |
| Muscle electrical test | 27 | $1,107 | $17 |
Who their Medicare patients are
115 Original Medicare patients in 2024. Average age 74 · Women 44% · Also on Medicaid 24% · Health risk score 1.33. At or below the middle of the specialty; the typical neuropsychiatry clinician is at 1.55.
Conditions among them: High blood pressure 47% · Depression 28% · Diabetes 17% · Coronary heart disease 17% · Atrial fibrillation 17% · Cancer 15% · Chronic kidney disease 14% · COPD 14% · Heart failure 13% · Stroke 13% · Dementia 10%.
The office billed $244,618, Medicare allowed $65,318 and paid $47,557; for 475 services of 20 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 115 | 475 | 74 | 1.33 | $244,618 | $47,557 |
| 2023 | 123 | 449 | 73 | 1.35 | $213,797 | $39,319 |
| 2022 | 191 | 595 | 74 | 1.41 | $269,205 | $51,737 |
| 2021 | 221 | 846 | 73 | 1.34 | $356,243 | $74,433 |
| 2020 | 219 | 721 | 73 | 1.35 | $243,545 | $51,987 |
| 2019 | 252 | 774 | 73 | 1.35 | $183,181 | $55,515 |
| 2018 | 243 | 692 | 74 | 1.44 | $185,964 | $59,925 |
| 2017 | 248 | 695 | 74 | 1.44 | $222,599 | $62,713 |
| 2016 | 209 | 822 | 74 | 1.39 | $289,482 | $82,782 |
| 2015 | 135 | 350 | 73 | 1.38 | $111,943 | $37,412 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 8 services
| Long return visit (40+ min) | 65 | $14,726 | $119 |
| Return visit (30+ min) | 48 | $5,398 | $78 |
| Face injection for nerve paralysis | 12 | $4,886 | $148 |
| Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | 11 | $4,055 | $131 |
| Injection of chemical for paralysis of nerve muscles on arm or leg, 1-4 muscles, first extremity | 12 | $2,469 | $80 |
| Muscle electrical test | 28 | $1,235 | $17 |
| Short return visit (20+ min) | 17 | $1,159 | $61 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, first 15 minutes with qualified health professional | 11 | $546 | $39 |
2022: 8 services
| Long return visit (40+ min) | 115 | $23,109 | $113 |
| Return visit (30+ min) | 77 | $7,874 | $83 |
| Face injection for nerve paralysis | 13 | $4,271 | $147 |
| Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | 14 | $4,257 | $122 |
| Injection of chemical for paralysis of nerve muscles on arm or leg, 1-4 muscles, first extremity | 15 | $2,897 | $80 |
| Muscle electrical test | 33 | $1,283 | $17 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, first 15 minutes with qualified health professional | 14 | $834 | $42 |
| Short return visit (20+ min) | 15 | $798 | $50 |
2021: 9 services
| Long return visit (40+ min) | 136 | $31,785 | $119 |
| Return visit (30+ min) | 123 | $17,664 | $83 |
| Face injection for nerve paralysis | 12 | $4,701 | $157 |
| Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | 11 | $4,366 | $128 |
| Injection of chemical for paralysis of nerve muscles on arm or leg, 1-4 muscles, first extremity | 18 | $2,511 | $90 |
| Injection of chemical for paralysis of salivary glands on both sides of mouth | 15 | $2,498 | $86 |
| Short return visit (20+ min) | 37 | $2,416 | $59 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, first 15 minutes with qualified health professional | 28 | $2,202 | $42 |
| Muscle electrical test | 33 | $1,234 | $18 |
2020: 11 services
| Long return visit (40+ min) | 123 | $16,729 | $91 |
| Return visit (30+ min) | 109 | $11,776 | $67 |
| Telephone medical discussion with physician, 21-30 minutes | 39 | $4,654 | $72 |
| Face injection for nerve paralysis | 11 | $3,425 | $143 |
| Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | 13 | $2,980 | $115 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, first 15 minutes with qualified health professional | 24 | $2,460 | $43 |
| Injection of chemical for paralysis of salivary glands on both sides of mouth | 12 | $2,125 | $97 |
| Long return visit (40+ min) | 11 | $934 | $78 |
| Return visit (30+ min) | 13 | $823 | $59 |
| Muscle electrical test | 24 | $735 | $17 |
| Short return visit (20+ min) | 15 | $724 | $43 |
2019: 11 services
| Long return visit (40+ min) | 166 | $24,014 | $89 |
| Return visit (30+ min) | 107 | $8,679 | $65 |
| Face injection for nerve paralysis | 11 | $4,271 | $153 |
| Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | 11 | $3,194 | $103 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, first 15 minutes with qualified health professional | 38 | $3,017 | $40 |
| New patient visit (45+ min) | 22 | $2,478 | $113 |
| Injection of chemical for paralysis of salivary glands on both sides of mouth | 12 | $2,296 | $85 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, each additional 15 minutes with qualified health professional | 11 | $1,579 | $40 |
| Short return visit (20+ min) | 15 | $851 | $41 |
| Muscle electrical test | 18 | $822 | $17 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator | 24 | $460 | $15 |
2018: 10 services
| Long return visit (40+ min) | 139 | $19,277 | $87 |
| Long return visit (40+ min) | 69 | $7,407 | $99 |
| Electronic analysis and programming of implanted complex deep brain neurostimulator generator system, first hour | 16 | $4,281 | $165 |
| Return visit (30+ min) | 55 | $3,881 | $61 |
| New patient visit (45+ min) | 24 | $2,421 | $101 |
| New patient visit (60+ min) | 17 | $2,056 | $121 |
| Return visit (30+ min) | 25 | $1,840 | $68 |
| Extended office or other outpatient service, first hour | 16 | $1,755 | $110 |
| Ultrasonic guidance for needle placement | 21 | $897 | $26 |
| Muscle electrical test | 11 | $202 | $18 |
2017: 7 services
| Long return visit (40+ min) | 165 | $28,420 | $90 |
| Electronic analysis and programming of implanted complex deep brain neurostimulator generator system, first hour | 27 | $9,225 | $156 |
| New patient visit (60+ min) | 43 | $5,643 | $131 |
| Return visit (30+ min) | 51 | $4,424 | $67 |
| New patient visit (45+ min) | 24 | $2,646 | $110 |
| Extended office or other outpatient service, first hour | 19 | $2,146 | $107 |
| Ultrasonic guidance for needle placement | 20 | $1,318 | $27 |
2016: 6 services
| Long return visit (40+ min) | 163 | $35,144 | $95 |
| Electronic analysis and programming of implanted complex deep brain neurostimulator generator system, first hour | 30 | $16,762 | $161 |
| New patient visit (60+ min) | 62 | $9,427 | $152 |
| Return visit (30+ min) | 52 | $6,205 | $71 |
| Extended office or other outpatient service, first hour | 61 | $6,174 | $86 |
| Ultrasonic guidance for needle placement | 16 | $974 | $29 |
2015: 5 services
| Long return visit (40+ min) | 82 | $12,484 | $98 |
| New patient visit (60+ min) | 56 | $8,415 | $150 |
| Electronic analysis and programming of implanted complex deep brain neurostimulator generator system, first hour | 19 | $6,382 | $168 |
| Extended office or other outpatient service, first hour | 44 | $4,232 | $83 |
| Return visit (30+ min) | 21 | $1,744 | $70 |
Medicaid work
$402 in 2018
Medicaid paid $402 for 12 billed services this clinician did in 2018, up to 12 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 12 | $402 |
| 2018 | 12 | 1 | 12 | $402 |
Drugs they prescribed that Part D paid
$262,000
Pharmacies billed $262,000 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 751) in 2024. At or below the middle of the specialty; the typical neuropsychiatry clinician is at 0%.
681 generic and 70 brand-name prescriptions · $262,000 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Rytary | Parkinson's | 34 | $66,097 | $1,944 |
| Rasagiline Mesylate | None | 38 | $13,708 | $361 |
| Carbidopa-Levodopa | None | 172 | $9,888 | $57 |
| Carbidopa-Levodopa Er | None | 102 | $4,766 | $47 |
| Amantadine | None | 55 | $2,546 | $46 |
See all 13 drugs
| Rytary | Parkinson's | 34 | $66,097 | $1,944 |
| Rasagiline Mesylate | None | 38 | $13,708 | $361 |
| Carbidopa-Levodopa | None | 172 | $9,888 | $57 |
| Carbidopa-Levodopa Er | None | 102 | $4,766 | $47 |
| Amantadine | None | 55 | $2,546 | $46 |
| Ropinirole Er | None | 14 | $2,345 | $167 |
| Gabapentin | None | 55 | $1,351 | $25 |
| Rivastigmine | None | 20 | $969 | $48 |
| Clonazepam | None | 60 | $541 | $9 |
| Pregabalin | None | 22 | $414 | $19 |
| Baclofen | None | 22 | $399 | $18 |
| Propranolol | None | 14 | $390 | $28 |
| Pramipexole Dihydrochloride | None | 11 | $339 | $31 |
Year by year
| 2024 | 751 | 96 | 0% (0) | 9% | $262,000 |
| 2023 | 800 | 119 | 0% (0) | 10% | $195,668 |
| 2022 | 1,002 | 145 | 0% (0) | 10% | $172,464 |
| 2021 | 1,030 | 138 | 0% (0) | 6% | $168,650 |
| 2020 | 882 | 138 | 0% (0) | 7% | $186,500 |
| 2019 | 974 | 158 | 0% (0) | 8% | $201,791 |
| 2018 | 971 | 155 | None | 9% | $321,712 |
| 2017 | 917 | 137 | 0% (0) | 12% | $139,165 |
| 2016 | 848 | 131 | 0% (0) | 15% | $131,763 |
| 2015 | 619 | 84 | 0% (0) | 24% | $208,382 |
| 2014 | 468 | 60 | 0% (0) | 26% | $222,821 |
| 2013 | 127 | 27 | None | 15% | $26,354 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 14 drugs
| Rytary | Parkinson's | 30 | $63,794 | $2,126 |
| Trientine | None | 11 | $32,658 | $2,969 |
| Xadago | None | 13 | $27,491 | $2,115 |
| Ongentys | None | 12 | $15,221 | $1,268 |
| Carbidopa-Levodopa | None | 222 | $13,803 | $62 |
| Rasagiline Mesylate | None | 35 | $10,947 | $313 |
| Carbidopa-Levodopa Er | None | 94 | $7,152 | $76 |
| Amantadine | None | 44 | $2,934 | $67 |
| Rivastigmine | None | 36 | $1,104 | $31 |
| Gabapentin | None | 42 | $1,093 | $26 |
| Baclofen | None | 32 | $1,077 | $34 |
| Clonazepam | None | 66 | $587 | $9 |
| Propranolol | None | 14 | $222 | $16 |
| Pregabalin | None | 15 | $92 | $6 |
2022: 23 drugs
| Rytary | Parkinson's | 33 | $34,022 | $1,031 |
| Xadago | None | 12 | $23,722 | $1,977 |
| Rasagiline Mesylate | None | 41 | $21,037 | $513 |
| Carbidopa-Levodopa | None | 274 | $20,445 | $75 |
| Ongentys | None | 16 | $11,008 | $688 |
| Carbidopa-Levodopa Er | None | 114 | $8,841 | $78 |
| Trientine | None | 13 | $6,918 | $532 |
| Amantadine | None | 66 | $5,523 | $84 |
| Rivastigmine | None | 30 | $3,806 | $127 |
| Tetrabenazine | None | 13 | $3,427 | $264 |
| Carbidopa-Levodopa-Entacapone | None | 12 | $1,686 | $140 |
| Midodrine | None | 13 | $1,334 | $103 |
| Propranolol Hcl Er | None | 11 | $1,329 | $121 |
| Gabapentin | None | 59 | $1,158 | $20 |
| Baclofen | None | 33 | $963 | $29 |
| Pregabalin | None | 19 | $885 | $47 |
| Clonazepam | None | 58 | $818 | $14 |
| Propranolol | None | 16 | $605 | $38 |
| Pramipexole Dihydrochloride | None | 25 | $530 | $21 |
| Fludrocortisone Acetate | None | 11 | $458 | $42 |
| Quetiapine | None | 17 | $257 | $15 |
| Primidone | None | 12 | $179 | $15 |
| Sertraline | None | 15 | $98 | $7 |
2021: 19 drugs
| Rytary | Parkinson's | 34 | $39,810 | $1,171 |
| Carbidopa-Levodopa | None | 316 | $31,371 | $99 |
| Xadago | None | 12 | $22,208 | $1,851 |
| Rasagiline Mesylate | None | 32 | $11,940 | $373 |
| Carbidopa-Levodopa Er | None | 122 | $10,779 | $88 |
| Tetrabenazine | None | 20 | $6,955 | $348 |
| Rivastigmine | None | 41 | $5,653 | $138 |
| Amantadine | None | 59 | $5,653 | $96 |
| Gabapentin | None | 77 | $1,954 | $25 |
| Pramipexole Dihydrochloride | None | 27 | $1,228 | $45 |
| Baclofen | None | 25 | $823 | $33 |
| Clonazepam | None | 32 | $740 | $23 |
| Fludrocortisone Acetate | None | 17 | $584 | $34 |
| Donepezil | None | 25 | $326 | $13 |
| Propranolol | None | 11 | $310 | $28 |
| Pregabalin | None | 15 | $304 | $20 |
| Trihexyphenidyl | None | 14 | $274 | $20 |
| Quetiapine | None | 27 | $187 | $7 |
| Sertraline | None | 11 | $186 | $17 |
2020: 13 drugs
| Rytary | Parkinson's | 28 | $49,553 | $1,770 |
| Rasagiline Mesylate | None | 30 | $25,373 | $846 |
| Carbidopa-Levodopa | None | 299 | $23,668 | $79 |
| Xadago | None | 11 | $18,656 | $1,696 |
| Carbidopa-Levodopa Er | None | 128 | $8,766 | $68 |
| Amantadine | None | 41 | $3,873 | $94 |
| Rivastigmine | None | 27 | $2,406 | $89 |
| Pramipexole Dihydrochloride | None | 34 | $1,123 | $33 |
| Gabapentin | None | 42 | $776 | $18 |
| Propranolol | None | 15 | $556 | $37 |
| Donepezil | None | 24 | $362 | $15 |
| Clonazepam | None | 33 | $306 | $9 |
| Trihexyphenidyl | None | 16 | $297 | $19 |
2019: 19 drugs
| Rytary | Parkinson's | 14 | $32,833 | $2,345 |
| Rasagiline Mesylate | None | 41 | $29,424 | $718 |
| Carbidopa-Levodopa | None | 313 | $20,992 | $67 |
| Tetrabenazine | None | 16 | $18,377 | $1,149 |
| Xadago | None | 11 | $17,462 | $1,587 |
| Carbidopa-Levodopa Er | None | 136 | $9,755 | $72 |
| Entacapone | None | 13 | $8,539 | $657 |
| Neupro | None | 12 | $8,479 | $707 |
| Amantadine | None | 38 | $4,712 | $124 |
| Gabapentin | None | 44 | $1,621 | $37 |
| Midodrine | None | 25 | $1,389 | $56 |
| Propranolol | None | 12 | $733 | $61 |
| Pramipexole Dihydrochloride | None | 21 | $673 | $32 |
| Donepezil | None | 35 | $528 | $15 |
| Trihexyphenidyl | None | 19 | $371 | $20 |
| Clonazepam | None | 37 | $336 | $9 |
| Lorazepam | None | 19 | $253 | $13 |
| Quetiapine | None | 16 | $238 | $15 |
| Baclofen | None | 13 | $172 | $13 |
2018: 20 drugs
| Rasagiline Mesylate | 35 | $42,853 | $1,224 |
| Carbidopa-Levodopa | 310 | $19,368 | $62 |
| Carbidopa-Levodopa-Entacapone | 14 | $12,269 | $876 |
| Entacapone | 12 | $9,987 | $832 |
| Neupro | 15 | $9,661 | $644 |
| Amantadine | 44 | $8,108 | $184 |
| Carbidopa-Levodopa Er | 104 | $8,015 | $77 |
| Horizant | 12 | $4,647 | $387 |
| Gabapentin | 77 | $2,554 | $33 |
| Rivastigmine | 11 | $1,456 | $132 |
| Polyethylene Glycol 3350 | 16 | $868 | $54 |
| Quetiapine | 25 | $853 | $34 |
| Propranolol | 13 | $734 | $56 |
| Pramipexole Dihydrochloride | 25 | $663 | $27 |
| Trihexyphenidyl | 15 | $624 | $42 |
| Baclofen | 22 | $412 | $19 |
| Divalproex | 12 | $328 | $27 |
| Clonazepam | 35 | $286 | $8 |
| Sertraline | 13 | $283 | $22 |
| Donepezil | 20 | $239 | $12 |
2017: 22 drugs
| Rasagiline Mesylate | 26 | $23,048 | $886 |
| Carbidopa-Levodopa | 298 | $16,925 | $57 |
| Entacapone | 24 | $15,491 | $645 |
| Carbidopa-Levodopa-Entacapone | 20 | $13,865 | $693 |
| Carbidopa | 14 | $11,128 | $795 |
| Neupro | 13 | $8,071 | $621 |
| Amantadine | 37 | $6,060 | $164 |
| Carbidopa-Levodopa Er | 115 | $5,667 | $49 |
| Horizant | 13 | $4,861 | $374 |
| Pramipexole Dihydrochloride | 54 | $2,037 | $38 |
| Rivastigmine | 13 | $1,654 | $127 |
| Polyethylene Glycol 3350 | 13 | $1,086 | $84 |
| Gabapentin | 58 | $991 | $17 |
| Trihexyphenidyl | 14 | $509 | $36 |
| Quetiapine | 16 | $448 | $28 |
| Zonisamide | 12 | $427 | $36 |
| Tizanidine | 13 | $313 | $24 |
| Propranolol | 11 | $173 | $16 |
| Clonazepam | 31 | $158 | $5 |
| Donepezil | 19 | $124 | $7 |
| Baclofen | 15 | $121 | $8 |
| Sertraline | 16 | $106 | $7 |
2016: 16 drugs
| Carbidopa | 30 | $20,861 | $695 |
| Entacapone | 31 | $19,191 | $619 |
| Azilect | 21 | $16,277 | $775 |
| Carbidopa-Levodopa | 262 | $11,742 | $45 |
| Carbidopa-Levodopa Er | 108 | $5,770 | $53 |
| Amantadine | 43 | $5,670 | $132 |
| Polyethylene Glycol 3350 | 36 | $1,746 | $48 |
| Quetiapine | 16 | $702 | $44 |
| Tizanidine | 12 | $691 | $58 |
| Gabapentin | 35 | $679 | $19 |
| Pramipexole Dihydrochloride | 56 | $644 | $12 |
| Propranolol | 15 | $288 | $19 |
| Olanzapine | 19 | $167 | $9 |
| Donepezil | 15 | $157 | $10 |
| Zonisamide | 12 | $129 | $11 |
| Baclofen | 15 | $128 | $9 |
2015: 16 drugs
| Xenazine | 24 | $124,023 | $5,168 |
| Carbidopa-Levodopa-Entacapone | 63 | $25,486 | $405 |
| Azilect | 27 | $21,665 | $802 |
| Entacapone | 12 | $6,957 | $580 |
| Carbidopa-Levodopa | 144 | $6,508 | $45 |
| Amantadine | 15 | $3,243 | $216 |
| Carbidopa-Levodopa Er | 56 | $2,568 | $46 |
| Quetiapine | 30 | $974 | $32 |
| Pramipexole Dihydrochloride | 19 | $769 | $40 |
| Sertraline | 37 | $581 | $16 |
| Olanzapine | 30 | $365 | $12 |
| Trazodone | 12 | $245 | $20 |
| Polyethylene Glycol 3350 | 11 | $226 | $21 |
| Risperidone | 12 | $117 | $10 |
| Donepezil | 14 | $105 | $8 |
| Baclofen | 14 | $70 | $5 |
2014: 11 drugs
| Xenazine | 22 | $124,298 | $5,650 |
| Azilect | 37 | $24,230 | $655 |
| Carbidopa-Levodopa-Entacapone | 19 | $9,111 | $480 |
| Carbidopa-Levodopa | 104 | $5,725 | $55 |
| Entacapone | 13 | $5,169 | $398 |
| Amantadine | 27 | $3,854 | $143 |
| Carbidopa-Levodopa Er | 59 | $2,269 | $38 |
| Pramipexole Dihydrochloride | 22 | $1,616 | $73 |
| Trazodone | 12 | $248 | $21 |
| Quetiapine | 19 | $200 | $11 |
| Sertraline | 24 | $165 | $7 |
2013: 2 drugs
| Carbidopa-Levodopa | 28 | $1,220 | $44 |
| Carbidopa-Levodopa Er | 14 | $645 | $46 |
Money from drug and device companies
$701 in 2025
| 2025 | 2 | 5 | None | $701 |
| 2019 | 1 | 1 | None | $223 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
See all 5 published payments
| Medtronic | Travel · 2025-12-15 | None | $614 |
| Medtronic | Travel · 2025-12-15 | None | $10 |
| Abbvie | Meals · 2025-05-09 | Vyalev | $27 |
| Abbvie | Meals · 2025-04-04 | Vyalev | $32 |
| Abbvie | Meals · 2025-01-07 | Vyalev | $18 |
See earlier years (2019)
2019: $223
| Boston Scientific | Spectra Wavewriter | $223 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Biogen, Inc. · Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of Biib054 in Participants With Parkinson'S Disease · 2019 | Their institution | $235,107 |
| Biogen, Inc. · Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Biib054 in Participants With Parkinson'S Disease · 2020 | Their institution | $120,415 |
| Biogen, Inc. · Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Biib054 in Participants With Parkinson'S Disease · 2021 | Their institution | $63,861 |
| Eli Lilly and Company · Effect of Ly3154207 on Cognition in Mild To Moderate Parkinsons Disease Dementia Pdd - the Presence Study · 2020 | Their institution | $52,334 |
| Biogen, Inc. · A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, With An Active-Treatment Dose-Blinded Period, To Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Biib054 in Subjects With Parkinson'S Disease · 2022 | Their institution | $2,641 |
| Eli Lilly and Company · Effect of Ly3154207 on Cognition in Mild To Moderate Parkinsons Disease Dementia Pdd - the Presence Study · 2021 | Their institution | $1,130 |
| Eli Lilly and Company · Effect of Ly3154207 on Cognition in Mild To Moderate Parkinsons Disease Dementia Pdd - the Presence Study · 2019 | Their institution | $1,038 |
| Eli Lilly and Company · Effect of Ly3154207 on Cognition in Mild To Moderate Parkinsons Disease Dementia Pdd - the Presence Study · 2020 | This clinician | $800 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1053545822
- Licence
- CA A113191California A113191: Current · expires 2027-11-30
- Trained
- University of Vermont College of Medicine, 2009
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 2084N0600X (2084N0600X); Neurology (2084N0400X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2009-05-08
- NPI last updated
- 2023-11-10
- NPI record certified
- 2023-11-10
This is when the NPI record was last certified, not a medical board exam.